课题基金 / 基金详情

Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and Maintenance

Disordered Regulation of Wnt/beta-catenin Signaling in MPNST Development and Maintenance
MPNST 发育和维持中 Wnt/β-catenin 信号传导的紊乱调节
批准号:
9304341
负责人:
DAVID ANDREW LARGAESPADA
金额:
$49.19万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-15 至 2019-06-30

项目摘要

项目成果

DAVID ANDREW LARGAESPADA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们进行了两个大型筛选来鉴定驱动MPNST形成或维持的基因:1)在人类MPNST细胞系中进行shRNA筛选,以及2)在小鼠MPNST模型中进行基于睡美人(SB)转座子的插入突变筛选。两种研究方法都确定了Wnt/ atenin调节通路是MPNST维持的关键介质。初步数据证实Wnt/ atenin通路是MPNST维持所必需的,并且可以使用小分子靶向。值得注意的是,我们发现了在MPNST中起作用的- atenin激活的多种机制。我们的建议集中在这些方面。Aim 1是基于我们的数据表明,基因或药物激活的- atenin破坏复合体降低- atenin水平,降低靶基因表达,抑制MPNST细胞存活和增殖。Aim 2基于数据显示,一些MPNSTs由于与上游EIF3E基因的转录融合而异位表达Wnt/ α - atenin激活剂R-spondin 2 (RSPO2),这是我们最近在人类结直肠癌中发现的一种机制。Aim 3是基于揭示- atenin靶基因PITX2在MPNST细胞存活中起关键作用的数据。我们的目标有两个:确定MPNST中- atenin去调控的分子格局,并对MPNST中Wnt/ - atenin通路的干预关键靶点进行全面的临床前评估,为在人类患者中进行有效的临床试验奠定基础。在互补的技能和资源的基础上,合作项目已经建立了成功的合作关系。大量正交的初步数据支持了本文的基本假设。
英文摘要
DESCRIPTION (provided by applicant): We carried out two large screens to identify genes driving MPNST formation or maintenance: 1) An shRNA screen in human MPNST cell lines, and 2) a Sleeping Beauty (SB) transposon- based insertional mutagenesis screen in a mouse model of MPNST. Both research approaches identified Wnt/�atenin-regulated pathways as critical mediators of MPNST maintenance. Preliminary data confirms that the Wnt/�atenin pathway is required for MPNST maintenance and can be targeted using small molecules. Remarkably, we identified multiple mechanisms of activation of �atenin that operate in MPNST. Our proposal focuses on these. Aim 1 is based on our data demonstrating that genetic or pharmacological activation of the �atenin destruction complex reduce �atenin levels, reduce target gene expression, and inhibit cell survival and proliferation in MPNST. Aim 2 is based on data showing that some MPNSTs ectopically express a Wnt/�atenin activator R-spondin 2 (RSPO2) due to transcript fusion with the upstream EIF3E gene, a mechanism we recently identified in human colorectal cancer. Aim 3 is based on data revealing that the �atenin target gene PITX2 plays a critical role in MPNST cell survival. Our goals are two-fold: to define the molecular landscape of �atenin de- regulation in MPNST, and perform a thorough pre-clinical evaluation of critical targets for intervention in the Wnt/�atenin pathway in MPNST, setting the stage for effective clinical testing in human patients. The Co-PIs have established a successful collaborative relationship built on complementary skills and resources. Abundant and orthogonal preliminary data support the basic hypothesis of this proposal.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrated Immune Engineering for Poor Prognosis Cancers
  • 批准号:
    10700921
  • 项目类别:
  • 资助金额:
    $186.91万
  • 财政年份:
    2021
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Integrated Immune Engineering for Poor Prognosis Cancers
  • 批准号:
    10270392
  • 项目类别:
  • 资助金额:
    $192.1万
  • 财政年份:
    2021
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
  • 批准号:
    10439480
  • 项目类别:
  • 资助金额:
    $57.74万
  • 财政年份:
    2020
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
  • 批准号:
    10653687
  • 项目类别:
  • 资助金额:
    $57.18万
  • 财政年份:
    2020
  • 负责人:
    DAVID ANDREW LARGAESPADA
  • 依托单位:
海外基金